A brilliant new @Nature synthesis of what we know about Alzheimer's disease pathogenesis, which is non-linear, with discrete phases (Figure), and notable inflection and transition points. Also helps to explain why symptoms do not correlate with underlying pathology. nature.com/articles/s41586-0…

Link to full piece: communitymorgue.com/p/the-fi…

Around age 50 your blood monocytes (Micro 2) begin a "hostile takeover" replacement of your brain microglia immune cells (Micro 1) and can promote inflammation. Two impressive studies made this remarkable discovery independently with different methods. In conversation with their lead authors, @juliabelk and Nathan Zemke erictopol.substack.com/p/two…

Speakers also include Sir Tony Kouzarides, Coleen Murphy, Gio Silva Garcia, @senergystic, Ali Shilatifard, @AdamsBioAging @Yael_David__ Francois Fuks, and more! #Epigenetics #Aging

✨The SenNet program aims to map and characterize senescent cells across age, tissue, and species. Discover research and opinion emerging from the SenNet project in a new cross-journal collection in the Nature portfolio ✨nature.com/immersive/s43587-…

One of the biggest challenges in longevity science isn't discovering interventions that might slow aging. It's figuring out how to prove they work in people. In Part 2 of my conversation with Dr. Brianna Stubbs, scientist at the Buck Institute for Research on Aging, we explore what may be one of the most important—and least discussed—frontiers in geroscience: building the clinical research infrastructure needed to bring aging-targeted therapies into mainstream medicine. Brianna leads an impressive portfolio of clinical studies spanning ketones, frailty, exercise, metabolism, AI-driven biomarkers, and aging measurement. We also discuss several ambitious ARPA-H initiatives aimed at creating a regulatory pathway for gerotherapeutics. Some of the topics we cover include: 🔹 How should we measure biological aging in clinical trials? 🔹 What is "intrinsic capacity," and could it become a new clinical endpoint? 🔹 Can wearables and AI improve how we assess aging? 🔹 What will it take for the FDA to approve therapies that target aging biology? 🔹 Why clinical trial design—not just drug discovery—may determine the future of longevity medicine. One of the themes that emerges throughout our discussion is that progress in longevity medicine won't come from a single breakthrough molecule. It will also require better biomarkers, smarter clinical trials, new regulatory frameworks, and collaboration between basic scientists, clinicians, data scientists, regulators, and industry. These aren't the topics that usually make headlines, but they may ultimately have the greatest impact on whether geroscience fulfills its promise. 🎥 Watch the full conversation here: piped.video/watch?v=kM6wL5dC…